The potential for modified insulin molecules to possess increased mitogenic potencies relative to human insulin has been recognised ever since a prototype rapid-acting analogue, insulin X10 (B10Asp), was found to dose-dependently increase the incidence of mammary tumours in female Sprague-Dawley rats [8], [9]. The gene discussed is INS; the disease is breast cancer.